anti-EGFR/HER3 bispecific antibody drug-conjugate (Biocytogen Pharmaceuticals)

N/A

Report date: 2025/06/11 10:54:08

Base Information

Drug Nameanti-EGFR/HER3 bispecific antibody drug-conjugate (Biocytogen Pharmaceuticals)
Drug Alias NameBCG-019-BLD-1102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 modulatorsDNA topoisomerase I inhibitorsEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A